Dr. Shapiro Discusses Bosutinib in CML

Mark Shapiro, MD, PhD
Published Online: Monday, Dec 23, 2013

Mark Shapiro, MD, PhD, Global Medical Affairs Lead, Hematology Programs, Pfizer, discusses bosutinib as treatment for patients with CML.

Shapiro says bosutinib is the fourth TKI to be approved for the treatment of CML. The mechanism of action of bosutinib is similar to other TKIs, Shapiro says, but there are some fundamental differences. Bosutinib targets the BCR-ABL kinase and inhibits the Src kinase.

Shapiro says the most significant difference among the compounds is their tolerability profile. Each of these compounds has their own set of adverse events.

Subsequent to the approval of bosutinib was ponatinib, Shapiro says, which was recently temporarily withdrawn from the market in the United States.


Mark Shapiro, MD, PhD, Global Medical Affairs Lead, Hematology Programs, Pfizer, discusses bosutinib as treatment for patients with CML.

Shapiro says bosutinib is the fourth TKI to be approved for the treatment of CML. The mechanism of action of bosutinib is similar to other TKIs, Shapiro says, but there are some fundamental differences. Bosutinib targets the BCR-ABL kinase and inhibits the Src kinase.

Shapiro says the most significant difference among the compounds is their tolerability profile. Each of these compounds has their own set of adverse events.

Subsequent to the approval of bosutinib was ponatinib, Shapiro says, which was recently temporarily withdrawn from the market in the United States.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 20th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 24, 20172.0
Publication Bottom Border
Border Publication